Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide OD vs OW PK in Healthy Subjects
NCT02557620Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide concentration-time curve from 0 to 168 hours. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02557620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557620.